A

Alexion

Global biopharmaceuticals focusing on rare diseases

Medical Director - Clinical Development

Biology & BiotechPosted on Nov 9
Full-timeBoston, MA, USA

About the Job

Requirements

  • An MD or international equivalent is required.
  • At least 3 years of clinical experience, preferably within industry, is required.
  • Experience as a medical monitor for clinical trials is required.
  • Publication in peer-reviewed journals is required.

Responsibilities

  • Design and execute multiple clinical studies or clinical programs.
  • Represent Clinical Development on the Global Program Team and present at management and review committees, including the Clinical Document Review Committee and Development and Commercial Steering Committee.
  • Work with clinical study teams to prepare study-related documents, including protocols, charters, statistical summary reports, meeting presentations, publications, and clinical sections of regulatory documents.
  • Select appropriate advisory board participants and guide the team in preparing for meetings.
  • Evaluate available information about diseases of interest to the therapeutic area and the competitive landscape, and synthesize it to support dissemination and incorporation into clinical development programs, asset plans, and therapeutic area strategy.

Desired Qualifications

  • Board certification.
  • Knowledge of the assigned therapy area and ability to interpret, discuss, and represent trial- or program-level data.
  • At least 5 years of industry experience in clinical development.
  • Experience with medical responsibilities on a cross-functional team.
  • Basic statistical knowledge.
  • Understanding of general and specific therapeutic principles.
  • Experience designing industry-sponsored clinical trials.
  • Broad experience in clinical trial methodology, statistics, data analysis, and interpretation.
  • Experience authoring study essential documents, Clinical Study Reports, and regulatory documents.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs